Allogene Therapeutics Inc

+0.39 (+1.66%)
Regulatory, Other Pre-Announcement

Allogene Reports Results From Studies Of ALLO-501 And ALLO-501A In Relapsed/Refractory Non-Hodgkin Lymphoma

Published: 05/19/2021 21:39 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Cd19 Forum Highlights Positive Results From Phase 1 Studies of Allo-501 and Allo-501a in Relapsed/refractory Non-hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021.
Allogene Therapeutics Inc - Overall Response Rate (orr) of 75% and Cr Rate of 50% Across Histologies in Car T NaÏve Patients.
Allogene Therapeutics Inc - 98% of Enrolled Patients Received Allo-501 With a Median Time of 5 Days From Enrollment to Start of Therapy.
Allogene Therapeutics - Initiation of Pivotal Trial of Allo-501a Planned for Late 2021.
Allogene Therapeutics Inc - Interim Phase 1 Alpha2 Data Demonstrated a Comparable Efficacy and Safety Profile for Allo-501a Relative to Allo-501.
Allogene Therapeutics Inc - During Phase 1 Allo-501 Alpha Trial Study, There Were Five Treatment-emergent Deaths in Absence of Disease Progression.